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Abstract
Purpose Inconsistent evidence exists for greater satiety after medium-chain triglycerides (MCT) or conjugated linoleic 
acid (CLA) compared to long-chain triglycerides (LCT). Furthermore, the mechanisms are poorly understood and effects 
in people with a healthy weight and those with overweight/obesity have not been compared. This study aimed to compare 
appetite responses in these groups and examine the mechanisms behind any differences.
Methods Fifteen participants with healthy weight (BMI: 22.7 ± 1.9 kg·m−2) and fourteen participants with overweight/
obesity (BMI: 30.9 ± 3.9 kg·m−2) consumed a breakfast containing either 23.06 g vegetable oil (CON), 25.00 g MCT oil 
(MCT), or 6.25 g CLA and 16.80 g vegetable oil (CLA). Appetite, peptide YY (PYY), total ghrelin (TG), β-hydroxybutyrate, 
and gastric emptying (GE) were measured throughout. Energy intake was assessed at an ad libitum lunch and throughout 
the following ~ 36 h.
Results Neither MCT nor CLA decreased ad libitum intake; however MCT decreased day 1 energy intake (P = 0.031) and 
the 48-h period (P = 0.005) compared to CON. MCT delayed GE (P ≤ 0.01) compared to CON, whereas CLA did not. PYY 
and TG concentrations were not different (P = 0.743 and P = 0.188, respectively), but MCT increased β-hydroxybutyrate 
concentrations compared to CON (P = 0.005) and CLA (P < 0.001). β-hydroxybutyrate concentrations were higher in par-
ticipants with overweight/obesity (P = 0.009).
Conclusion Consumption of MCT reduces energy intake in the subsequent 48 h, whereas CLA does not. Delayed gastric 
emptying or increased β-hydroxybutyrate concentrations may mediate this.
Keywords Appetite · Energy intake · Food intake · Gut-peptide hormones · Ketones · Lipids
Introduction
Satiety is the process that inhibits further eating after the ces-
sation of an eating episode and is characterised by declined 
hunger and increased fullness [1]. Satiety enhancement is 
desirable to consumers as it strengthens internal cues of sati-
ety and can result in calorie reduction without associated 
feelings of deprivation and hence provide increased dietary 
compliance [2]. Because dietary fats are the most energy 
dense macronutrient, fats with functional properties such 
as enhanced satiety have gained popularity in recent years 
in response to the continuing prevalence of overweight and 
obesity [2–5]. ‘Functional fats’ are fats which replace other 
fats with deleterious effects, or which promote beneficial 
effects to health [6]. Medium-chain triglycerides (MCT) are 
the most well-researched and currently popular ‘functional 
fat’ in terms of satiety, but there are various other fats which 
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also have the potential to beneficially affect weight status 
and health [7].
MCT have been reported to increase satiety [8–11] and 
increase energy expenditure [12, 13] compared to more 
commonly consumed long-chain triglycerides (LCT). This 
is thought to be achieved through rapid absorption due to 
the smaller molecular weight of MCT [14], which not only 
leads to the entirety of the MCT bolus to be absorbed at the 
point of ingestion (unlike LCT where some remains in the 
intestine until further consumption [15], but also the pro-
duction of ketone bodies such as β-hydroxybutyrate (β-HB) 
[16], which is thought to be anorexigenic [17]. Other than 
cholecystokinin (CCK), which has been extensively studied 
in response to MCT [18–23], the hormonal response to MCT 
is not well understood. In one study, a MCT preload led to 
increased peptide YY (PYY) and leptin levels and decreased 
active ghrelin compared to LCT, but not GLP-1 or total ghre-
lin (TG) [24]. In another study, although both MCT and LCT 
increased PYY concentrations, the increase was greater after 
LCT [25]. Our understanding of the hormonal response to 
MCT is, therefore, limited.
Conjugated linoleic acid (CLA) is another fat with poten-
tial to increase satiety, although evidence for this is limited. 
The long-term effect of CLA on reducing body fat is widely 
reported [26–29], and various animal studies have reported 
decreased intake after CLA supplementation [30–34]. To the 
author’s knowledge, there is only one study to date that has 
specifically examined the effect of CLA on satiety in humans 
[11]. In that study consumption of CLA led to increased sati-
ety compared to LCT, but less than MCT [11]. To date, there 
is no mechanistic data to support CLA-mediated satiety.
One potential limitation to the literature examining lipids 
and satiety to date is the lack of participants with overweight 
and obesity included in studies. It is well known that appetite 
control is altered with increased adiposity, with attenuated 
postprandial PYY and ghrelin responses [35] amongst other 
alterations in appetite hormones. Gastric emptying (GE) has 
also been shown to be faster in overweight and obesity [36, 
37], which may be related to reduced concentrations of pan-
creatic polypeptide [38]. Therefore, studies examining lipids 
and satiety should aim to examine the effects in participants 
with overweight and obesity in order to confirm the find-
ings observed in lean and healthy weight persons are cor-
roborated in this population arguably the ‘target group’ of 
research aiming to elucidate methods of increasing satiety.
A more complete understanding of the mechanisms 
behind MCT related satiety, as well as further study into 
CLA related satiety is warranted. This study was designed 
to compare the appetite and hormonal responses to MCT and 
CLA and the effects on subsequent intake, as well as com-
pare the effects in participants of healthy weight to partici-
pants with overweight and obesity, which has not previously 
been investigated. This study also aimed to quantify the GE 
response to MCT and CLA in comparison to a control lipid 
in order to evaluate any potential satiety effect caused by 
differences in GE rates. Therefore, the aim of this study was 
to compare the satiety response to MCT and CLA in par-
ticipants with a healthy weight to those with overweight/
obesity.
Methods
Trial registration
The current study is registered on the ISRCTN clinical trial 
registry (ISRCTN23021181).
Design
All participants completed three trials in a random order. 
They consumed a breakfast smoothie on three non-consec-
utive days, each of which contained one of the three test 
oils. ‘Trials’ consist of the standardisation period, day of the 
laboratory visit and the following day, and these trial periods 
were separated by a minimum of 48 h and a maximum of 
10 days for male participants. For female participants, all tri-
als were conducted during the first 10 days of the menstrual 
cycle, again with a minimum of 48 h between trials. This 
was achieved by asking the participant how many days it 
had been since the start of their menstrual cycle, as indicated 
by the onset of menstruation, to ensure they were in the fol-
licular phase of their cycle. Female participants were stud-
ied across no more than two consecutive menstrual cycles. 
Participants who were taking progestogen only contracep-
tive pills were asked to continue taking these throughout 
the course of the study and were not restricted on dates for 
testing. After breakfast, data were collected for 3 h, after 
which participants consumed an ad libitum buffet lunch, and 
completed weighed food records for the remainder of the day 
and the following 24 h.
Participants
Inclusion criteria were as follows: 18–65 years of age, weight 
stable for the 3 months leading up to the commencement of 
the study, be taking no medication which could affect appe-
tite, unrestrained eaters and with a BMI of 18.5–24.9 kg·m−2 
(healthy weight) or a BMI of 25–40 kg·m−2 (overweight/
obese). Participants with a BMI of 25–30 kg·m−2 were also 
required to have minimum body fat percentages of 25% 
and 32% (for males and females, respectively) in order to 
ensure that greater weight was not due to greater muscle 
mass [39]. After institutional ethical approval (UREC: 
171082), participants (healthy weight: M: 10, F: 5, age: 
25 ± 5 years, weight: 67.3 ± 9.6 kg, BMI: 22.7 ± 1.9 kg·m2, 
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body fat: 18.8 ± 5.5%; overweight/obese: M: 7, F: 7, age: 
34 ± 9 years, weight: 91.2 ± 18.2 kg, BMI: 30.9 ± 3.9 kg·m2, 
body fat: 33.1 ± 6.5%) who were recruited through social 
media, posters and through a research activity mailing list, 
completed a medical questionnaire and gave their written 
consent.
Standardisation
In the 24  h preceding the first trial, participants were 
required to record all food and drink consumed, along with 
any physical activity undertaken. This diary was replicated 
in the 24 h preceding the remaining trials. Strenuous phys-
ical activity and alcohol were to be avoided in this 24-h 
period, and participants were asked to keep caffeine intake 
at habitual levels.
Protocol
Participants attended a screening session at the Oxford 
Brookes Centre for Nutrition and Health, where all experi-
mental trials took place, to determine eligibility. Height was 
measured (to the nearest 0.1 cm) using a mobile stadiom-
eter (Seca 217, Seca, Birmingham, UK), and body mass and 
body fat percentage (to the 0.1 kg and 0.1%, respectively) 
were measured using a body composition monitor (BC-418 
MA, Tanita, Amsterdam, the Netherlands). If eligible based 
on BMI and BF% criteria, participants completed the Three-
Factor Eating Questionnaire [40], Dutch Eating Behaviour 
Questionnaire [41] and Medical History Questionnaire. Par-
ticipants were provided with commercially available digital 
weighing scales (Colour Match Digital Scale, Argos, Milton 
Keynes, UK) and a standardisation booklet, with instructions 
on how to complete this for the standardisation procedure.
Each trial consisted of one visit to the laboratory, where 
participants arrived between 7:00 and 9:00 am after a 
10–12  h overnight fast. All trials for each participant 
started at the same time. Participants rested for 10 min in a 
seated position before a cannula was inserted into an ante-
cubital vein for repeated samples. After baseline samples 
were taken, participants were provided with the breakfast 
smoothie which was the vehicle for the experimental oils 
and were instructed to consume this within 5 min. Imme-
diately upon completion of the breakfast, participants rated 
the palatability of the drink on visual analogue scales (VAS). 
Participants then rested for 3 h whilst measures of gastric 
emptying, subjective sensations of appetite and nausea and 
blood samples were taken. At 3 h participants consumed an 
ad libitum buffet lunch until satiation, after which they were 
free to leave the laboratory. Participants were instructed to 
complete weighed food diaries for the remainder of the day 
and for the following 24 h.
Test breakfast
Participants were provided with 250 mL of a commercially 
available mango and passion fruit smoothie (Tesco Stores 
ltd, Cheshunt, UK; 591.9 kJ (139.5 kcal) 0.4 g fat, 32.2 car-
bohydrate g, 1.5 g protein) to which one of three lipids was 
added: (1) 23.06 g vegetable oil (Con; rapeseed oil, Tesco 
Stores Ltd., Cheshunt, UK), (2) 25.00 g MCT oil [MCT; 
Muscleform, Norfolk, UK, (caproic acid 2%, caprylic acid 
50–60%, capric acid 30–45% and lauric acid 3%)] or (3) 
6.25 g CLA oil [CLA; USN UK Ltd., Longbridge, UK (5 g 
of CLA, 50% c9,t11 isomers and 50% t10,c12 isomers)] 
mixed with 16.80 g vegetable oil (rapeseed oil, Tesco Stores 
Ltd., Cheshunt, UK). MCT are less energy dense than LCT 
(8.3 kcal/g compared to 9.0 kcal/g) [42] and so the amount 
of fat added to the smoothie was to achieve an equal energy 
content across the test meals. The smoothie and test fat were 
mixed using a food blender for 60 s and were consumed 
within 5 min. to avoid separation of the fats and were all 
served at room temperature.
Gastric emptying
GE was measured by adding 100 mg 13C octanoic acid (Euri-
sotop, France) to the breakfast which resulted in an increase 
in 13CO2 in the breath. Octanoic acid is a medium-chain 
fatty acid which is rapidly oxidised to 13CO2 after passage 
through the pyloric sphincter. Breath samples were collected 
into 12 mL exetainers (Labco, Lampete, UK) in duplicate 
every 15 min for 3 h. The appearance of 13CO2 was meas-
ured using isotope ratio mass spectrometry (ABCA, Ser-
con Ltd., Crewe, UK) and results were expressed relative 
to Vienna Pee Dee Belemnite (V-PBD), an international 
standard of known 13C abundance. Carbon dioxide pro-
duction rates were estimated to be 5 mmol  CO2·min−1·m−2 
body surface area [43] and body surface area calculated from 
height and weight according to Haycock et al. [44]. The rate 
of appearance in the breath was used to calculate gastric 
emptying half time (Thalf) and lag phase (Tlag) according 
to Ghoos et al. [45] and the latency (Tlat) and ascension 
(Tasc) according to Schommartz et al. [46]. Thalf is the time 
required to empty 50% of the ingested meal, Tlat is the initial 
delay of the cumulative exhalation curve, Tlag is the time 
between meal ingestion and the start of gastric emptying, 
and Tasc refers to the high rates of 13CO2 exhalation between 
the Tlag and Thalf.
Subjective sensations
Hunger, fullness, desire to eat (DTE), prospective food con-
sumption (PFC) and nausea were assessed using paper 100-
mm visual analogue scales (VAS) where 0 mm indicated 
‘not at all’ and 100 mm indicated ‘extremely’. These were 
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recorded at 0 h (baseline), 0.5 h, 1 h, 1.5 h, 2 h, and 3 h. To 
test the palatability of the breakfasts, participants also rated 
the appearance, aroma, flavour, pleasantness and texture on 
100 mm VAS immediately after the breakfast, with anchors 
of ‘Do not like at all’ and ‘Like extremely much’ at 0 mm 
and 100 mm, respectively.
Blood sampling
Blood was obtained from a superficial antecubital vein via 
cannulation at 0 h, 0.5 h, 1.0 h, 2.0 h and 3.0 h. Cannu-
las were kept patent by flushing with 0.9% wt/vol sodium 
chloride saline (Steripod Normal Saline, Mölnlycke Health 
Care Ltd, Bedfordshire, UK) immediately after samples. 
The first 1 mL of each sample was drawn and discarded, 
after which 6-mL samples were drawn and immediately 
dispensed into pre-chilled tubes containing  K2EDTA (Fis-
cher Scientific, Leicester, UK). 1 mL of blood was used for 
the determination of TG, and the remaining 4 mL was used 
for the determination of PYY and β-HB. The 1 mL aliquot 
was dispensed into an EDTA tube. All samples were centri-
fuged for 10 min in a refrigerated (4 °C) centrifuge at 3500g. 
The supernatant of each sample was removed and stored in 
labelled Eppendorf tubes, and immediately frozen at − 80 °C 
for later analysis.
Plasma concentrations of β-HB (Cayman Chemical, MI, 
US), PYY (RayBiotech, Cambridge Bioscience, Cambridge, 
UK) and TG (Merck Millipore, MA, US) were measured 
by enzyme-linked immunosorbent assay (ELISA). ELISAs 
were read using a plate reader to quantify absorbance (β-
HB and PYY: ELx800, BioTek, VT, US; TG: SpectraMax 
i3x, Molecular Devices, CA, US). Provided quality controls 
with acceptable high and low ranges ensured precision of 
analysis. Mean intra-variation of the plates was 5.2% (range: 
2.8–10.6%), 7.3% (range: 2.8–13.5%), and 3.9% (range: 
1.5–8.8%), for β-HB, PYY and TG, respectively.
Food intake
Three hours after participants consumed the test breakfast, 
they were presented with an ad libitum pasta lunch made 
with meat-free Bolognese sauce (Tesco, Cheshunt, UK). In 
order to ensure each batch of pasta was as closely matched 
at possible for energy density, pasta was made approximately 
1 h prior to serving in identical amounts, in a standardised 
cooking procedure. Once cooked, 490 g of the Bolognese 
sauce was mixed thoroughly, before the pasta was distributed 
into four bowls of approximately 350 g. Immediately before 
serving, the pasta was reheated for 7 s, cooled for 2 min, 
then weighed and served. This timing allowed bowls to be 
replaced when ~ 50–75% of the bowl had been consumed, 
in order to remove the external cue of an empty bowl ter-
minating the meal. This allowed fresh pasta to be delivered 
every ~ 180 s, although this was adjusted if the participant 
was not consuming ~ 50% of the bowl when a fresh bowl was 
replaced. Participants were explicitly instructed to “eat until 
you are comfortably full”. Water was consumed ad libitum 
during the first trial and this amount was repeated in the 
following trials. Energy intake at the ad libitum meal was 
calculated from manufacturers packaging and weighed food 
diaries were analysed using the software package Nutritics 
Professional (Dublin, Ireland). Participants received training 
and a detailed instruction booklet on how to complete these 
food records at the screening session, in order to maximise 
record accuracy.
Statistical analysis
Data were analysed using SPSS v.25 software for windows 
(SPSS inc. Somers, NY, USA). Area under the curve (AUC) 
values for appetite sensations and for plasma concentra-
tions of hormones vs time curves were calculated using 
the trapezoidal rule. Plasma hormone concentrations were 
analysed as raw values and as relative to baseline concentra-
tions (delta). A repeated-measures mixed ANOVA revealed 
no differences in baseline values for any appetite parameter 
(all P > 0.05), and so a repeated measures mixed ANOVA 
was run without baseline as a covariate. Repeated measures 
mixed ANOVAs were used to examine differences between 
energy intakes between groups at the ad libitum lunch, for 
the rest of the day, the following 24 h and over the 48-h 
period, as well as to investigate trial order effects. Two-way 
repeated measures mixed ANOVA were used to examine 
differences between trials over time for plasma hormone 
concentrations between groups. Cohen’s d was calculated 
and interpreted according to Cohen [47]. All data were sub-
ject to checks for normality using the Shapiro–Wilk test. 
Where appropriate, post-hoc analyses were conducted using 
the Bonferroni adjustment. Significance was accepted at the 
alpha level of P < 0.05. Data are expressed as means ± SD 
unless otherwise stated.
Results
Energy intake
There were no differences in food intake at the ad libitum 
meal, during the rest of the day (from weighed food records), 
total day 1, day 2 or across the 48-h period between healthy 
weight and overweight/obese participants (all P > 0.05). As 
such the food intake results are presented for all participants 
as a whole.
Energy intake at the ad libitum lunch was significantly 
different (F(2,54) = 3.739, P = 0.033, η2 = 0.122), with 
decreased intake in MCT (4093 ± 1664 kJ) compared to CLA 
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(4643 ± 1887 kJ, P = 0.033, d = 0.31). There was no differ-
ence between CON (4500 ± 1620 kJ) and MCT (P = 0.256) 
or CLA (P = 1.00). There was a trend towards a main 
effect of trial for the weighed food records, (F(2,50) = 3.054, 
P = 0.056, η2 = 0.109). There was a significant effect of trial 
on intake over day 1 (F(2,50) = 4.855, P = 0.012, η2 = 0.163), 
as MCT led to lower overall energy intake compared to 
both CON (9679 ± 3907 kJ vs 11,530 ± 4076 kJ, P = 0.031, 
d = 0.46) and CLA (9679 ± 3907 kJ vs 11,057 ± 4540 kJ, 
P = 0.026, d = 0.33). There was no difference between CON 
and CLA (P = 1.00). There was a trend for lower energy 
intake in day 2 (F(2,48) = 2.746, P = 0.074, η2 = 0.103), with 
a tendency for MCT to lead to non-significantly lower intake 
compared to CLA (8469 ± 3106 kJ vs 10,436 ± 4912 kJ, 
P = 0.072, d = 0.49). There was a significant effect of trial on 
intake over the whole 48-h period (F(2,48) = 7.232, P = 0.004, 
η2 = 0.232), with intakes lower in MCT compared to both 
CON (18,512 ± 5855 kJ vs 21,307 ± 6222 kJ, P = 0.005, 
d = 0.46) and CLA (18,512 ± 5855 kJ vs 22,187 ± 7756 kJ, 
P = 0.005, d = 0.54; Fig. 1).
Appetite sensations
There were no differences between participants with a 
healthy weight compared to those with overweight/obe-
sity (all P > 0.05), so results are presented for the group 
as a whole. There were no differences between trials for 
hunger (F(2,54) = 0.914, P = 0.389, η2 = 0.033), fullness 
(F(2,54) = 1.793, P = 0.176, η2 = 0.062), DTE (F(2,54) = 0.772, 
P = 0.467, η2 = 0.028), or PFC (F(2,54) = 1.060, P = 0.342, 
η2 = 0.038). There was, however, a significant effect of 
trial on nausea (F(2, 54) = 7.663, P = 0.003, η2 = 0.221), with 
significant higher AUC values in MCT compared to CON 
(P = 0.007). Analysis of the results indicated this was driven 
by high nausea ratings for 8 out of 29 participants in MCT.
Palatability
There was a trend for the MCT breakfast to be more 
pleasant than CON or CLA, but this was not significant 
(F(2,56) = 2.711, P = 0.075, η2 = 0.088). There were no other 
differences in any palatability measure (all P > 0.192).
β‑Hydroxybutyrate
Baseline concentrations of β-HB did not differ between tri-
als (F(2,50) = 0.747, P = 0.428, η2 = 0.029). Absolute time-
averaged β-HB concentrations were significantly higher in 
the overweight/obese group by 0.110 ± 0.09 mM (P = 0.009, 
d = 0.98), but there was no interaction of trial, time and 
group (F(8,176) = 0.649, P = 0.586, η2 = 0.029). There was a 
significant main effect of trial (F(2,44) = 12.810, P < 0.001, 
η2 = 0.368), and post-hoc tests showed MCT led to greater 
β-HB concentrations compared to both CON (P = 0.005, 
d = 0.55) and CLA (P < 0.001, d = 0.53). There was no 
main effect of time (F(4,88) = 1.216, P = 0.311, η2 = 0.052), 
Fig. 1  Energy intake (kJ) at 
the ad libitum lunch, over the 
course of the trial day (test 
breakfast, ad libitum lunch and 
weighed food record), day 2, 
and over the entire 48-h period. 
Values are presented as means, 
with vertical bars representing 
standard deviation. Asterisk 
(*) denotes MCT significantly 
different from both CON 
and CLA, hash (#) denotes a 
non-significant trend for lower 
intake in MCT compared to 
CLA. Significance is accepted 
as P < 0.05
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but there was a interaction of trial and time (F(8,176) = 2.842, 
P = 0.045, η2 = 0.114), with β-HB rising significantly in 
MCT in the postprandial period compared to CON (Fig. 2a).
There was a significant difference in AUC of β-HB con-
centrations (F(2,50) = 17.268, P < 0.001, η2 = 0.409), with 
significantly higher values in MCT compared to both CON 
(P = 0.001, d = 0.60) and CLA (P < 0.001, d = 0.64). Delta β-
HB concentrations also followed the same pattern, with sig-
nificant effects of trial (F(2,48) = 8.649, P = 0.001, η2 = 0.265), 
but not time (F(3,72) = 0.292, P = 0.831, η2 = 0.012). 
Similarly there was a significant interaction of time and trial 
(F(6,144) = 4.084, P = 0.012, η2 = 0.145), as β-HB concentra-
tions elevated rapidly to a greater extent in MCT compared 
to CON or CLA (Fig. 2b).
PYY
Baseline concentrations of PYY did not differ between tri-
als (F(2,44) = 2.150, P = 0.145, η2 = 0.089). PYY was also 
not affected by group (P = 0.170), and thus data are shown 
Fig. 2  Absolute β-HB concen-
trations (a), percentage change 
from baseline (b) and total 
AUC (c) in participants with 
healthy weight (black symbols; 
n = 15) and overweight/obesity 
(white symbols; n = 14). Data 
are means with vertical error 
bars representing SD (some 
error bars have been removed 
for clarity). Asterisk (*) 
denotes significantly different at 
P < 0.05
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for all participants as a whole group. There were no main 
effects for trial (F(2,44) = 0.235, P = 0.743, η2 = 0.011) or time 
(F(4,88) = 0.373, P = 0.765, η2 = 0.017). There was a trend for 
an interaction between trial and time, as PYY concentra-
tions increased postprandially in CON, peaking at 60 min 
and decreasing thereafter, whereas PYY levels decreased 
until 60 min in MCT, then began to rise, and PYY decreased 
throughout the whole 180 min in CLA. This interaction 
was non-significant (F(8,176) = 2.136, P = 0.099, η2 = 0.088; 
Fig. 3a). There was no difference between trials for PYY 
AUC (P = 0.647). Delta PYY concentrations showed no 
effect for trial, despite a trend for suppressed concentra-
tions in CLA compared to both other trials (F(2,46) = 2.962, 
P = 0.078, η2 = 0.114) or time (F(3,69) = 0.723, P = 0.542, 
η2 = 0.030). There was, however, a significant interaction of 
time and trial (F(6,138) = 3.458, P = 0.012, η2 = 0.131), with 
delta PYY peaking quickest in CON at 60 min, whereas 
delta PYY in MCT slowly increased after an transient 
decrease, and CLA continually decreased throughout the 
whole 180 min (Fig. 3b).
Total ghrelin
There was no difference between participants with a healthy 
weight and those with overweight/obese for absolute TG 
concentrations (F(1,17) = 1.112, P = 0.306, η2 = 0.061), and 
3-way interaction of trial, time and group (F(8,136) = 1.037, 
P = 0.396, η2 = 0.058), and so results are presented for 
Fig. 3  Absolute PYY concen-
trations (a), percentage change 
from baseline (b), and total 
AUC (c) for all participants 
(n = 29). Data are means with 
vertical error bars representing 
SD (some error bars have been 
removed for clarity)
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the data as a whole. There were no main effects for trial 
(F(2,36) = 1.786, P = 0.188, η2 = 0.090) but there was a main 
effect of time (F(4,72) = 19.678, P < 0.001, η2 = 0.522). TG 
concentrations dropped postprandially, reaching nadir at 
90 min. Post-hoc tests revealed all time points were signifi-
cantly lower than baseline other than 180 min (all P < 0.01), 
where concentrations increased to non-significant levels. 
There was no interaction of time and trial (F(8,144) = 1.827, 
P = 0.131, η2 = 0.092; Fig.  4a). A repeated measures 
ANOVA revealed a significant change from baseline TG 
concentrations (F(2,48) = 3.511, P = 0.038, η2 = 0.128). 
Post-hoc tests showed that values were tended to be lower 
in MCT compared to CON (P = 0.06, d = 0.23), but there 
was no difference between CLA and CON (P = 0.575), or 
MCT and CLA (P = 0.496). Delta TG followed a similar 
pattern as absolute values, as there were no main effects for 
trial, although this approached significance (F(2,40) = 3.119, 
P = 0.055, η2 = 0.135) as was the same for the interaction 
of trial and time (F(6,120) = 2.107, P = 0.087, η2 = 0.095). 
There was, however, a significant main effect of time 
Fig. 4  Absolute total ghrelin 
concentrations (a), percentage 
change from baseline (b) and 
total AUC (c) for all participants 
(n = 29). Data are means with 
vertical error bars representing 
SD (some error bars have been 
removed for clarity)
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(F(3,60) = 16.265, P < 0.001, η2 = 0.449), with delta concen-
trations decreasing to a similar extent below baseline in all 
trials (Fig. 4b).
Gastric emptying
There was no effect of group on Thalf (P = 0.939), Tlag 
(P = 0.463), Tlat (P = 0.267) or Tasc (P = 0.842), and so 
gastric emptying parameters are presented for all partici-
pants as a whole group. There were significant effects of 
trial on Thalf (F(2,42) = 15.906, P < 0.001, η2 = 0.431), Tlag 
(F(2,42) = 29.120, P < 0.001, η2 = 0.581), Tlat (F(2,42) = 10.120, 
P < 0.001, η2 = 0.325) and Tasc (F(2,42) = 15.502, P < 0.001, 
η2 = 0.425). Post-hoc tests showed MCT delayed all GE 
parameters compared to both CON and CLA (Thalf: 
P = 0.001, d = 1.37; P = 0.001, d = 1.12; Tlag: P < 0.001, 
d = 1.68; P < 0.001, d = 1.49; Tlat: P = 0.01, d = 0.95; 
P < 0.001, d = 1.24; Tasc: P = 0.001, d = 1.39; P = 0.002, 
d = 1.08). There were no differences between CON and 
CLA (all P = 1.00). There was also no interaction of trial 
and group in Thalf (F(2,42) = 0.2001, P = 0.164, η2 = 0.087) or 
Tasc (F(2,42) = 1.757, P = 0.196, η2 = 0.077), Table 1.
Trial order effects
There were no trial order effects for energy intake for the 
group as a whole (P > 0.05, η2 > 0.030) or when account-
ing for participants with healthy weight or overweight/obe-
sity (P > 0.05, η2 > 0.039). GE followed this pattern, with 
no evidence of a trial order effect for the group as a whole 
(P > 0.05, η2 > 0.050) or for when accounting for weight sta-
tus (P > 0.05, η2 > 0.026).
Discussion
The primary finding of this study was that MCT did not 
reduce energy intake at the first meal after their consump-
tion, but reduced energy intake over the following 48 h com-
pared to LCT. This was not affected by weight status, and 
appears to be mediated by a delaying of GE, an increase in 
the anorexigenic ketone body β-HB, or a combination of 
the two. It is possible the tendency for decreased energy 
intake at the ad libitum lunch was caused by β-HB which 
then contributed to the decrease in overall energy intake. 
Conversely, CLA does not alter energy intake in comparison 
to a LCT control.
The literature surrounding MCT and satiety is equivo-
cal, with studies reporting decreased energy intake after 
MCT [8–10, 48] and others reporting no effect [49, 50]. 
The results of the current study corroborate previous find-
ings from our laboratory [11] which found no difference in 
energy intake at the first meal post consumption of MCT 
and LCT, but decreased energy intake in later eating epi-
sodes and overall energy intake throughout the course of 
the day after MCT consumption. However, in our previous 
study, CLA also reduced energy intake to a similar extent, 
whereas the results of the current study do not support that 
finding. To our knowledge, only our previous study has 
investigated the acute effect of CLA on satiety and energy 
intake in humans, although CLA has been shown to decrease 
feed intake in mice [33], which is reportedly due to sup-
pressed expression of the potent orexigenic neurons neu-
ropeptide Y and Agouti-related peptide [34]. In the CLA 
arm of the current study, participants consumed a mixture of 
CLA and LCT. This dosage was based on our previous work 
Table 1  Gastric emptying (GE) half time, lag phase, latency phase and ascension time of all participants (n = 29)
Values are means ± SD
CON control trial, MCT medium-chain triglyceride trial, CLA conjugated linoleic acid trial
*Significantly different from both CON and CLA
# Significant interaction of trial and group. Significance accepted at the P < 0.05 level
GE parameter CON MCT CLA
Total Total Total
Half time (min) 121.8 ± 46.5 269.8 ± 168.9* 131.4 ± 78.3
Lag phase (min) 44.8 ± 16.5 77.7 ± 22.6* 45.3 ± 20.7
Latency phase (min) 36.8 ± 15.4 51.1 ± 14.9* 34.7 ± 11.5
Ascension time (min) 165.6 ± 40.2 317.0 ± 177.6* 178.4 ± 79.3
Healthy-weight Overweight/obese Healthy-weight Overweight/obese Healthy-weight Overweight/obese
Half time (min) 105.7 ± 43.7 136.6 ± 45.4 308.5 ± 204.1 228.0 ± 114.1 114.5 ± 46.0 149.7 ± 101.8
Lag phase (min) 38.5 ± 16.2 50.6 ± 15.1 83.2 ± 25.3 71.7 ± 18.5# 41.4 ± 16.2 49.6 ± 24.7
Latency phase (min) 32.1 ± 10.4 41.1 ± 18.2 54.1 ± 18.3 47.9 ± 9.7# 32.9 ± 10.7 36.7 ± 12.5
Ascension time (min) 152.3 ± 43.0 177.9 ± 34.3 357.4 ± 211.1 273.5 ± 126.9 161.3 ± 44.4 197.0 ± 104.1
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which used the same dosage in the same vehicle (breakfast 
smoothie) [11]. Information regarding the composition of 
the CLA (i.e. which isomers in what ratio) was not avail-
able in the previous study, and thus it is possible that the 
CLA given in that study is different to the one given in the 
current study. Due to its effect on gene expression relating 
to the regulation of triglyceride storage, the t10,c12 isomer 
is reported to exert the greatest anti-adipogenic effect [51], 
but whether this also relates to acute satiety is unknown. In 
the current study, participants ate the ad libitum lunch at a 
fixed timepoint, 180 min after consumption of the breakfast. 
In the previous study, participants were to request the lunch, 
and CLA led to a significantly delayed time-to-meal request 
than the control [11]. On the basis that the ad libitum lunch 
was later in the day, this may partly explain why there was 
reduced intake later in the day compared to the control in 
that study, whereas we report no difference in the current 
study. Due to the distinct lack of research examining CLA 
and satiety, it is difficult to draw clear conclusions, but this 
study does not support the finding that CLA reduces energy 
intake.
The mechanisms behind MCT-enhanced satiety are still 
under debate. Early research has shown that the absorption 
of MCT is quicker than LCT, bypassing the lymphatic sys-
tem and traveling directly to the liver via the portal vein, 
where they undergo β-oxidation [52]. However, we show 
delayed GE after MCT compared to LCT. This is in contrast 
with previous studies showing that MCT do not stimulate 
CCK secretion (a potent fat-related inhibitor of GE) [53] 
or accelerate small-bowel transit time [54]. These findings 
are also disparate to previous research showing that gas-
tric emptying was accelerated following MCT (compared 
to carbohydrate which is known to empty faster than LCT) 
[55]. However, we have now seen delays in gastric emp-
tying compared to LCT across several studies [56]. MCT 
may delay GE due to a higher osmolarity than LCT, which 
is well known to be inversely related to GE [57]. GE and 
hunger are known to be correlated [58], so slower GE may 
be the primary mechanism by which satiety is induced on 
the MCT trial. Our results also indicate MCT lead to the 
production of the ketone body β-hydroxybutyrate, which is 
thought to possess anorexigenic properties via a glucose-
sparing mechanism and via central action in the brain [17, 
59, 60]. Decreases of blood glucose have been shown to 
promote hunger in order to promote food intake and prevent 
hypoglycaemia [61], and thus if β-hydroxybutyrate atten-
uates a decrease in blood glucose, hunger should also be 
attenuated. β-hydroxybutyrate rose significantly in response 
to MCT ingestion in the current study, yet returned to levels 
similar to baseline by the end of the data collection period, 
similarly to previous findings investigating the ketone body 
[60]. Therefore, suppressed energy intake later in the day is 
unlikely to be mediated by this mechanism.
St-Onge et al. [24] reported no differences in TG con-
centrations after meals containing MCT or LCT, but greater 
suppression of acylated ghrelin in LCT. They also report a 
greater postprandial rise in PYY after MCT compared to 
LCT. Our results support these findings, as we report no 
difference in TG concentrations after breakfasts containing 
LCT, MCT or CLA. Our findings do not, however, recipro-
cate those regarding PYY, as we found no difference in abso-
lute PYY concentrations and a significantly greater increase 
from baseline at 60 min in LCT. However, whereas PYY 
concentrations peaked at 60 min and started to decrease in 
LCT, concentrations continued to rise in MCT, and failed 
to reach a plateau. It is possible that PYY levels may have 
increased further and remained elevated, as it has been 
shown previously that PYY can remain elevated for beyond 
300 min [62], which may explain decreased intake later in 
the day and in the following 24 h. As PYY secretion is initi-
ated by the sensing of nutrients in the gastrointestinal lumen 
[63], this may be linked to the delay in gastric emptying 
caused by MCT. Further work is needed, utilising a longer 
sampling period, in order to investigate these speculations. 
Neary et al. [64] reported that only acylated ghrelin exerts 
orexigenic effects as only the acylated form can bind to the 
growth hormone secretagogue receptor type 1a (GHS-R1a) 
in order to activate the lateral hypothalamus: the orexigenic 
centre of the brain. More recent evidence has suggested that 
lipids suppress total and acylated ghrelin to the same extent 
[65], and thus TG may act as a surrogate marker for acylated 
ghrelin. Regardless, future work should include acylated 
ghrelin analysis to confirm this.
This study is, to our knowledge, the first study to compare 
the effect of MCT and CLA in healthy weight to overweight/
obese individuals. Increased body fat has been shown to 
decrease circulating PYY concentrations as well as attenu-
ated postprandial suppression of ghrelin [66]. Studies exam-
ining appetite regulation should take differences in these 
populations into consideration, as findings in lean or healthy 
weight individuals may not represent those with increased 
body mass or adiposity. We report no differences in energy 
intake between individuals with healthy weight and indi-
viduals with overweight or obesity; thus MCT exert same 
effect in both groups. This is despite our reporting increased 
β-HB and accelerated Tlag and Tlat in overweight/obese 
participants after MCT ingestion, where these parameters 
were delayed further in overweight/obese participants in 
LCT and CLA.
This study has shown novel findings that MCT exerts 
similar effects in healthy weight and obese individuals, via a 
MCT-mediated delay in gastric emptying, elevation in β-HB 
concentrations and suppression of ghrelin concentrations to 
a similar extent as LCT. However, there are several limita-
tions to consider. We found that nausea was significantly 
higher in the MCT trial compared to both CON and CLA. 
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This confounds our findings, as decreases in energy intake 
may be mediated by nausea, rather than altered appetite reg-
ulation; which would discredit the use of MCT. However, 
the differences in nausea scores were driven by high nausea 
in a small number (8/29) of participants. Why MCT causes 
nausea in some but not others is currently unknown and if 
MCT are to be developed or promoted as a satiating food 
product, which must be investigated to ensure their toler-
ability first. Practically, a product which causes nausea is 
unlikely to gain popularity or be utilised chronically, which 
would be the aim if they were designed to be utilised in 
weight loss strategies. Our results indicate most individuals 
do not respond negatively to MCT ingestion and that adverse 
effects are not related to palatability as this tended to be 
higher for the MCT. We also examined TG and not acylated 
(active) ghrelin, as discussed above.
In conclusion, we have shown that a single feeding of 
MCT reduce energy intake over a 48-h period compared to 
equicaloric LCT, whereas CLA do not. This may be medi-
ated by increased β-HB concentrations or via delayed gas-
tric emptying, which in turn may lead to prolonged elevated 
PYY concentrations; although further work is needed to 
confirm these hypotheses. We also show that MCT exert a 
similar effect in participants with healthy weight and over-
weight or obesity.
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